Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults

OBJECTIVE: Both sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) demonstrated cardiovascular benefits in randomized controlled trials of patients with type 2 diabetes (T2D) generally <65 years old and mostly with cardiovascular disease. We...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetes Care
Asıl Yazarlar: Patorno, Elisabetta, Pawar, Ajinkya, Bessette, Lily G., Kim, Dae H., Dave, Chintan, Glynn, Robert J., Munshi, Medha N., Schneeweiss, Sebastian, Wexler, Deborah J., Kim, Seoyoung C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Diabetes Association 2021
Konular:
Cardiovascular and Metabolic Risk
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7896266/
https://ncbi.nlm.nih.gov/pubmed/33495295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc20-1464
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller